Home|Journals|Articles by Year|Audio Abstracts

Original Article

Molecular docking study on the interaction between 2-substituted-4,5-difuryl Imidazoles with different Protein Target for antileishmanial activity.

Julio Alberto Rojas Vargas, America García Lopez, Mariana Mariana Castro Piñol.


Leishmaniasis is a disease that is caused by the protozoa Leishmania and is considered the second-highest cause of death worldwide by parasitic infection. Looking for the right chemotherapy against leishmaniases has been difficult because of the high toxicity of the most effective drugs. Computational Chemistry plays an important role in the research of new possible medicines. In this work, docking analysis was carried out to study the effects of nine 2-substituted-4,5-difuryl Imidazole on Leishmania arginase, Leishmania trypanothione synthetase amidase and Leishmania trypanothione reductase and results were compared with three known drugs, and with targets potential inhibitors. ∆G, Ki and binding interactions in the targets active sites were reported. Results show that 4, 5-di (furan-2-yl)-2-(5-(4-nitrophenyl) furan-2-yl)-1H imidazole and 4-(5-(4, 5-di (furan-2-yl)-1H-imidazol-2-yl) furan-2-yl) benzoic acid are promising leads, so further study of these compounds is recommended.

Key words: Antileishmanial activity, Molecular docking, 2-substituted-4,5-difuryl imidazoles, Leishmania arginase, Leishmania trypanothione synthetase amidase, Leishmania trypanothione reductase

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.